Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer
Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer Patients With Intermediate/High Risk Primary Disease or Biochemical Recurrence After Treatment
Sponsor: Five Eleven Pharma, Inc.
A PHASE1/PHASE2 clinical study on Prostate Cancer and Prostate Cancer Recurrent, this trial is ongoing. The trial is conducted by Five Eleven Pharma, Inc. and has accumulated 12 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jun 2022 — Jul 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Sep 2021 — Jun 2022 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Jan 2021 — Sep 2021 [monthly]
Recruiting PHASE1_PHASE2
▶ Show 7 earlier versions
-
Jun 2020 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
-
May 2020 — Jun 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2020 — May 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Jul 2019 — Feb 2020 [monthly]
Recruiting PHASE1_PHASE2
-
May 2019 — Jul 2019 [monthly]
Recruiting PHASE1_PHASE2
Phase: PHASE1 → PHASE1_PHASE2
-
Jun 2018 — May 2019 [monthly]
Recruiting PHASE1
-
Mar 2018 — Jun 2018 [monthly]
Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Five Eleven Pharma, Inc.
- Indiana University
For direct contact, visit the study record on ClinicalTrials.gov .